Expansion of the medical cannabis market in Brazil and regulatory challenges
Author Information
Author(s): Cláudia Du Bocage Santos Pinto, Ângela Esher, Cátia Verônica dos Santos Oliveira, Claudia Garcia Serpa Osorio-de-Castro
Primary Institution: Escola Nacional de Saúde Pública Sergio Arouca, Fundação Oswaldo Cruz
Conclusion
The regulatory framework for medical cannabis in Brazil is still developing, with significant challenges in ensuring safety and efficacy for patients.
Supporting Evidence
- Brazil spent around BRL 165 million on public supply of cannabis-derived products from 2015 to mid-2023.
- Only one cannabis-derived product is classified as a medicine in Brazil.
- Anvisa has authorized the import of cannabis-containing products under specific regulations.
- Only a few indications for cannabis use have high or moderate levels of evidence.
Takeaway
Brazil is trying to figure out how to safely use cannabis for medicine, but there are still a lot of rules and not enough proof that it works for many problems.
Potential Biases
Potential bias due to the influence of social pressure and litigation on the availability of cannabis products.
Limitations
The study highlights the lack of sufficient scientific evidence for many cannabis-derived products and the regulatory gaps in their approval and use.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website